Clinical trials · Washington, D.C., DC
Glioma clinical trials in Washington, D.C.
We’re tracking 37 recruiting glioma studies with a site in or near Washington, D.C. — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT04485559RecruitingPhase 1
Trametinib and everolimus for recurrent gliomas
This trial tests two drugs, trametinib and everolimus, for children and young adults with recurrent or progressive gliomas (a type of brain tumor). The goal is to see if this drug combination is safe and effective in treating these tumors.
Washington D.C., District of ColumbiaAges 1–25 - NCT03340506RecruitingPhase 4
Follow-on treatment study for dabrafenib and trametinib
This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.
Bethesda, MarylandAges 18–100 - NCT06344130RecruitingPhase 1
Shorter radiation for recurrent glioblastoma
This trial tests a new, shorter course of radiation therapy (called hypofractionation) for people with glioblastoma that has come back. It is for patients who have already had radiation and are doing well enough to consider another round.
Bethesda, MarylandAges 18–120 - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15 years+ - NCT06161519RecruitingPhase 1/Phase 2
PLX038 for brain tumors with MYC or MYCN changes
This study tests a new drug called PLX038 for people with brain or spinal cord tumors that have certain genetic changes (MYC or MYCN) or have come back after treatment. The drug is given as an infusion and targets tumor cells. The study aims to see if the drug is safe and effective for different types of these tumors.
Bethesda, MarylandAges 18–120 - NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT06326411RecruitingPhase 1
Testing NST-628 pills for advanced solid tumors with RAS/MAPK changes
This trial tests an experimental pill called NST-628 for people with advanced solid tumors that have specific genetic changes in the RAS/MAPK pathway. The goal is to see if it is safe and effective when other treatments are no longer working.
Fairfax, VirginiaAges 18 years+ - NCT05303519RecruitingPhase 3
Safusidenib for IDH1-mutant glioma after main treatment
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
Fairfax, VirginiaAges 18 years+ - NCT07831369RecruitingPhase 2
Drug combination for recurrent glioma
This trial tests a combination of three drugs—valproic acid, irinotecan, and simvastatin—to see if they can help people whose brain tumor (glioma) has come back despite earlier treatment. The goal is to slow or stop tumor growth.
Fairfax, VirginiaAges 18–98 - NCT04699773Recruiting
Laser treatment then focused radiation for new brain gliomas
This trial studies a two-step treatment for newly diagnosed high-grade glioma: first laser treatment (LITT) to target the tumor, followed by a shorter, more focused course of radiation. It may help shrink or control the tumor while limiting treatment time.
Columbia, MarylandAges 18 years+ - NCT06610682RecruitingEarly Phase 1
Plixorafenib for BRAF-mutated glioma
This study tests a new targeted drug called plixorafenib, either alone or combined with another drug (retifanlimab), for people with a BRAF-mutated brain tumor. The goal is to see if the drug can reach the brain and control the tumor, while checking for side effects.
Baltimore, MarylandAges 18 years+ - NCT04772456RecruitingPhase 1
MRI scan using a special sugar to study infiltrating brain tumors
This early study (Phase 1) tests a new kind of MRI that uses a special labeled sugar (pyruvate) to help learn how infiltrating gliomas behave in the brain. If you have a suspected or known infiltrating glioma and are having brain surgery or biopsy, this may help your doctors learn more about tumor metabolism and guide future care.
Baltimore, MarylandAges 18–80
Hear when a new Glioma trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Glioma trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting glioma studies listed above.
- National Institutes of Health Clinical Center · 4 studies
- Johns Hopkins University · 2 studies
- Central Maryland Radiation Oncology
- Children's National Medical Center
- Inova Schar Cancer
- Inova Schar Cancer Institute
- Maryland Proton Treatment Center
- National Institute of Health
What taking part in a glioma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there glioma clinical trials near Washington, D.C.?
- Yes. We're currently tracking 37 recruiting glioma studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a glioma study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a glioma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New glioma studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.